Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech has commenced an underwritten public offering of ordinary shares, combined with a concurrent private placement, targeting gross proceeds of approximately $125 million. The company intends to use the net proceeds to fund the continued development of its biosimilar assets, working capital, and general corporate purposes, including potential acquisitions or collaborations. BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.